Canada markets open in 1 hour 17 minutes

Eisai Co., Ltd. (ESALY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
59.42-0.78 (-1.30%)
At close: 03:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close60.20
Bid0.00 x 0
Ask0.00 x 0
Day's Range59.10 - 60.27
52 Week Range59.10 - 129.79
Avg. Volume20,041
Market Cap17.077B
Beta (5Y Monthly)0.37
PE Ratio (TTM)30.88
EPS (TTM)1.92
Earnings DateN/A
Forward Dividend & Yield1.43 (2.41%)
Ex-Dividend DateSep. 28, 2021
1y Target Est80.00
  • Motley Fool

    Biogen inc (BIIB) Q3 2021 Earnings Call Transcript

    Image source: The Motley Fool. Biogen inc (NASDAQ: BIIB)Q3 2021 Earnings CallOct 20, 2021, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning.

  • Reuters

    Eisai, Biogen start U.S. accelerated approval for new Alzheimer's drug

    Japanese drugmaker Eisai Co on Monday began its application process for its experimental drug for early Alzheimer's disease using an accelerated approval pathway, the same path that helped Eisai's development partner Biogen Inc win U.S. approval of its medication in June. The Biogen/Eisai drug Aduhelm was the first Alzheimer's treatment to win approval in nearly 20 years, but the Food and Drug Administration's (FDA) controversial use of the accelerated approval process - which authorizes drugs for severe conditions without strong proof of a benefit to patients - has come under heavy fire.

  • Zacks

    Citius (CTXR) Acquires Dr. Reddy's License for NHL Therapy

    Citius Pharmaceuticals (CTXR) acquires Dr. Reddy's exclusive license rights for E7777 to treat a rare form of NHL and other cancer indications.